“Health is the greatest gift, contentment the greatest wealth, faithfulness the best relationship.” – Buddha

 

PNA Spotlight: Dr. Aaron Cohen-Gadol

This month the PNA Spotlight focuses on Dr. Aaron Cohen-Gadol, a professor at Indiana University Department of Neurosurgery. He is the director of neurosurgical oncology and its fellowship, and co-director of the Signature Center for Brain and Neurological Tumors. Dr. Cohen-Gadol earned his undergraduate degree from the University
of California at San Diego and attended medical school at the University of Southern California. He then completed his residency training at Mayo Clinic in Rochester, Minnesota. He also completed fellowship training in two subspecialties: epilepsy surgery (Yale University) and skull base/cerebrovascular surgery (University of Arkansas.) In addition, Dr. Cohen holds a Master’s Degree in Clinical Research from Mayo Graduate School and an MBA from Kelley School of Business. His areas of interest include surgical treatment of complex intracranial tumors and vascular lesions.

He is the founder and president of The Neurosurgical Atlas (https://www.neurosurgicalatlas.com), a multimedia resource for neurosurgical techniques. Dr. Cohen-Gadol was kind enough to answer some questions posed by the PNA. His answers follow.

Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support

Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.

Sign up to get dedicated support:

Patients: Sign up for support | Recorlev® (levoketoconazole)

HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)

Have more questions? Call for more support at 1-844-444-RCLV (7258)

PNA Medical Corner: Somatotroph Adenoma in a Young Adult

This month the PNA Medical Corner spotlights an article co-authored by a member of the PNA, Dr. Ursula Kaiser, Chief of the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. The case report looks at early onset excess of growth hormone in the context of a somatotroph adenoma in a young adult.

Link: https://doi.org/10.1210/jcemcr/luad030

Early Onset GH Excess: Somatotroph Adenoma in a Young Adult

Featured News and Updates

The FDA has approved NGENLA (somatrogon-ghla)

The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

See the Press Release here>

News Articles November 2025

News Articles November 2025

Case report: from pituitary tumor to metastatic cancer

An article on Cureus.com looks at the case of a 35-year-old man with a lactrotroph pituitary adenoma that progressed to a metastatic pituitary carcinoma. In this rare case, the cancer is “resistant to surgery, radiation, and medical treatments.“  Read more: https://www.cureus.com/articles/348490-transformation-of-lactotroph-pituitary-adenoma-to-metastatic-pituitary-carcinoma-a-case-report#!/

Patient story: Musician Lou Gramm on his battle with a pituitary tumor

An article on blabbermouth.net features the pituitary story of musician Lou Gramm of the group “Foreigner”, who had surgery for a craniopharyngioma in 1997 after suffering headaches and memory loss.  Read more: https://blabbermouth.net/news/lou-gramm-says-he-couldnt-remember-the-words-to-foreigners-classic-songs-shortly-after-his-brain-surgery

Researchers use artificial intelligence to screen for childhood hormone deficiency

An article in EMJ Reviews looks at a study on whether artificial intelligence can predict growth hormone deficiency in children of short stature. The machine learning model examines MRI scans of the pituitary and has shown good results. In the future, this could lead doctors to order fewer invasive growth hormone stimulation tests for children. Read more: https://www.emjreviews.com/en-us/amj/radiology/news/mri-radiomics-model-predicts-childhood-hormone-deficiency/

Patient on off-label cabergoline develops impulse control disorder as tumor grows

An study in Cureus.com examines the case of a 19-year-old man with a prolactinoma who was given off-label cabergoline at three times the normal dose for ten years. He developed an impulse control disorder and a spending and gambling problem, and was lost to follow-up. Radiosurgery was rejected, as the patient was deemed unable to comply with the necessary follow-up regime. It was later discovered that his tumor was resistant to cabergoline and had grown and extended into the cavernous sinus, making it inoperable. Read more: https://www.cureus.com/articles/416467-giant-prolactinoma-resistant-to-high-dose-cabergoline-in-a-young-male-lost-to-follow-up#!/

 

Research Articles

November 2025 Research Articles

 Pituitary tumors


Interrogation of the cellular hierarchies reveals neoplastic evolution and therapeutic vulnerability in craniopharyngioma.

Zhang B, Zhang J, Li Z, Sheng H, Li H, Lu Y, Liu X, Xu Z, Huang Y, Zhu C, Wen Y, He X, Zhang L.Neuro Oncol. 2025 Oct 24:noaf249. doi: 10.1093/neuonc/noaf249. Online ahead of print.

 

Unusual Dual Brain Tumor Morphologies in an MEN1 Patient: A Case Report of Diagnostic Challenges and Methylation Insights.

Patel V, Aboud O, Barakat A.Int J Mol Sci. 2025 Oct 16;26(20):10065. doi: 10.3390/ijms262010065.

 

Pituitary surgery
Global Growth and Distribution of CyberKnife Stereotactic Radiosurgery: A Bibliometric Analysis.

Annagiri S, Hori YS, Persad ARL, Ustrzynski L, Emrich SC, Tayag A, Park DJ, Adler JR, Chang SD.Neurosurg Pract. 2025 Jul 10;6(3):e000150. doi: 10.1227/neuprac.0000000000000150. eCollection 2025 Sep.

 

Imaging

Combined Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in the Differential Diagnosis of Sellar Tumors: A Single-Centre Experience.

Korbecki A, Łukasiewicz M, Kacała A, Sobański M, Zdanowicz-Ratajczyk A, Szałata K, Dorochowicz M, Korbecka J, Trybek G, Zimny A, Bladowska J.J Clin Med. 2025 Oct 11;14(20):7168. doi: 10.3390/jcm14207168.


A swarm intelligence-driven hybrid framework for brain tumor classification with enhanced deep features.

Yonar A.Sci Rep. 2025 Oct 28;15(1):37543. doi: 10.1038/s41598-025-23820-3.

 

Acromegaly

Paltusotine: The first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly.

Sun Y, Lu D, Gao J.Drug Discov Ther. 2025 Oct 29. doi: 10.5582/ddt.2025.01109. Online ahead of print.

 

Hematological Malignancy in a Hypophysectomised Acromegalic Patient Under 4-Year Therapy with Somatostatin Analogues: From a Rib Lump Underlying Bone Plasmatocytoma Features to Multiple Myeloma.

Stanciu M, Cătană A, Ristea RP, Tanasescu D, Carsote M, Popa FL, Lebădă IC.Diagnostics (Basel). 2025 Oct 17;15(20):2623. doi: 10.3390/diagnostics15202623.

 

Cushing’s

Three Cases of Ectopic, Cyclic Cushing Syndrome: A New Square Wave Variant.

Martinez-Gil M, Tshimbombu TN, Li Yi Ang Y, Rodriguez MC, Yuen KCJ.JCEM Case Rep. 2025 Oct 28;3(12):luaf176. doi: 10.1210/jcemcr/luaf176. eCollection 2025 Dec.

 

Selective Hippocampal Subfield Atrophy Mediates Cognitive Decline in Cushing’s Disease.

Feng Z, Zhou T, Yan X, He K, Liu H, Yu X, Lu R, Ma Z, Yu X, Zhang Y.Brain Behav. 2025 Nov;15(11):e71030. doi: 10.1002/brb3.71030.

 

Hormonal health

 

Awareness of post-transplant endocrine disorders among kidney transplant clinicians: results of an Italian survey.

Pellegrini B, Cantaluppi V, Aimaretti G, Ferraresso M, Romagnoli J, Silvestre C, Comai G, Maggiore U, Leone F, Greco R, Maggiolini M, Provenzano M, Zaza G; Joint Committee of the Italian Society of Organ Transplantation and the Italian Society of Nephrology.J Endocrinol Invest. 2025 Oct 29. doi: 10.1007/s40618-025-02741-y. Online ahead of print.

 

 

 

 

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.